Innovid has received a mix of bullish and indifferent ratings from analysts in the last quarter. The average 12-month price target of $3.02 has increased by 37.27% over the past month, which indicates that analysts have a positive outlook on the stock. However, the mixed ratings suggest that there is still some uncertainty about the stock's future performance. Therefore, the short-term impact on the stock price is neutral.